IP is just as much about collaboration as exclusivity for oncology tech companies 14 May 13
IP advocacy group Ideas Matter showcased the pivotal role of IP in the development of cancer treatments at an event in London today. Representatives from a number of companies active in the field of cancer diagnostics attempted to counter the arguments put forward by IP sceptics by explaining the importance of IP to funding, product development, cross-industry collaboration and ultimately improving the quality of life for cancer sufferers.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
You have a great publication! It is the central professional journal in the field of intellectual assets.
Dr Lindsay Moore
CEO and president, KLM Inc Management Consultation
Adjunct Professor of Law, George Washington University Law School
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email